2020
Using a Collaborative, Virtual Discussion Platform to Mobilize Oncologic Expertise for the COVID-19 Pandemic.
Bejjani A, Burt L, Washington C, Terao M, Housri S, Housri N. Using a Collaborative, Virtual Discussion Platform to Mobilize Oncologic Expertise for the COVID-19 Pandemic. JCO Clinical Cancer Informatics 2020, 4: 794-798. PMID: 32897736, PMCID: PMC7529517, DOI: 10.1200/cci.20.00073.Peer-Reviewed Original ResearchConceptsGynecologic oncologyPediatric oncologyActive disease sitesCOVID-19 pandemicOncology patientsMedical oncologyClinical managementBreast cancerOncology expertsCare resourcesInitial experienceDisease sitesDisease typeOncologyWorldwide pandemicOncologistsRadiation oncologyHealth careCOVID-19Peer-reviewed informationSubstantial numberPandemicTotal numberPatientsCancer
2014
Significance of Phospho(Ser73)-K8 Expression in Women With Breast Cancer of Triple Negative Phenotype
Garg R, Housri N, Kongara S, Wu H, Schiff D, Moran M, Karantza V, Haffty B. Significance of Phospho(Ser73)-K8 Expression in Women With Breast Cancer of Triple Negative Phenotype. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s69-s70. DOI: 10.1016/j.ijrobp.2014.05.230.Peer-Reviewed Original ResearchIs There a Role for Postmastectomy Radiation Therapy After Complete Pathologic Response to Neoadjuvant Chemotherapy?
Housri N, Haffty B. Is There a Role for Postmastectomy Radiation Therapy After Complete Pathologic Response to Neoadjuvant Chemotherapy? Current Breast Cancer Reports 2014, 6: 38-44. DOI: 10.1007/s12609-013-0134-8.Peer-Reviewed Original ResearchPathologic complete responsePostmastectomy radiationNeoadjuvant chemotherapySmall primary tumorsAdvanced breast cancerComplete pathologic responseNode-negative diseasePostmastectomy radiation therapyInitial clinical stageTime of mastectomyMulti-institutional trialPatterns of practiceAdvanced diseasePathologic responseComplete responseClinical stagePrimary tumorBreast cancerRadiation therapyRadiation indicationsLower riskPatientsRadiation oncologistsRetrospective dataChemotherapy
2013
Non-White Women Are as Likely as White Women to Receive Hypofractionated Radiation Therapy for Breast Cancer, But Less Likely to Enroll in Hypofractionation Clinical Trials
Housri N, Khan A, Taunk N, Nelson C, Goyal S, Haffty B. Non-White Women Are as Likely as White Women to Receive Hypofractionated Radiation Therapy for Breast Cancer, But Less Likely to Enroll in Hypofractionation Clinical Trials. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s491. DOI: 10.1016/j.ijrobp.2013.06.1298.Peer-Reviewed Original Research
2008
Are Many Community Hospitals Undertreating Breast Cancer?
Gutierrez JC, Hurley JD, Housri N, Perez EA, Byrne MM, Koniaris LG. Are Many Community Hospitals Undertreating Breast Cancer? Annals Of Surgery 2008, 248: 154-162. PMID: 18650623, DOI: 10.1097/sla.0b013e31816c4030.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiopsy, NeedleBreast NeoplasmsCarcinoma, Ductal, BreastChemotherapy, AdjuvantCombined Modality TherapyFemaleFloridaHealth Care SurveysHospitals, CommunityHospitals, UniversityHumansImmunohistochemistryMastectomyMiddle AgedNeoplasm StagingOutcome Assessment, Health CarePractice Patterns, Physicians'Radiotherapy, AdjuvantRegistriesRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsLong-term outcomesTeaching hospitalCommunity hospitalBreast cancerPoor long-term outcomesFlorida Cancer Data SystemHigh-volume community hospitalsLow-volume hospitalsOverall survival rateBreast-conserving surgeryHigh-volume centersSignificant independent predictorsAdjuvant therapyAdvanced diseaseMultimodality therapySurvival benefitIndependent predictorsTreatment patternsDuctal carcinomaPatient outcomesPractice patternsBetter survivalStage IIIOperative casesTreatment approaches